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Brain edema is frequently shown after cerebral ischemia. It is an expansion of brain volume because
of increasing water content in brain. It causes to increase mortality after stroke. Agmatine, formed by
the decarboxylation of L-arginine by arginine decarboxylase, has been shown to be neuroprotective
in trauma and ischemia models. The purpose of this study was to investigate the effect of agmatine
for brain edema in ischemic brain damage and to evaluate the expression of aquaporins (AQPs).
Results showed that agmatine significantly reduced brain swelling volume 22h after 2 h middle
cerebral artery occlusion in mice. Water content in brain tissue was clearly decreased 24h after
ischemic injury by agmatine treatment. Blood–brain barrier (BBB) disruption was diminished with
agmatine than without. The expressions of AQPs-1 and -9 were well correlated with brain edema as
water channels, were significantly decreased by agmatine treatment. It can thus be suggested that
agmatine could attenuate brain edema by limitting BBB disruption and blocking the accumulation of
brain water content through lessening the expression of AQP-1 after cerebral ischemia.
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Introduction
Agmatine, formed by the decarboxylation of
L-arginine by arginine decarboxylase, was first dis-
covered in 1910. It is hydrolyzed to putrescine and
urea by agmatinase (Yang and Reis, 1999). Recently,
agmatine, arginine decarboxylase, and agmatinase
were found in mammalian brain (Li et al, 1994).
Agmatine is an endogenous clonidine-displacing
substance, an agonist for the two adrenergic and
imidazoline receptors, and an antagonist at
N-methyl-D-aspartate receptors (Li et al, 1994;
Reynolds, 1990). It has been shown that agmatine may
be neuroprotective in trauma and ischemia models
(Gilad et al, 1996; Kim et al, 2004; Yang and Reis,
1999; Yu et al, 2000). Agmatine was shown to protect
neurons against glutamate toxicity and this effect
was mediated through N-methyl-D-aspartate receptor
blockade, with agmatine interacting at a site located
within the N-methyl-D-aspartate channel pore
(Olmos et al, 1999). Despite this work, the mode
and site(s) of agmatine action in the brain have not
been fully understood and yet to be undefined.
However, nitric oxide synthases generate nitric oxide
by sequential oxidation of the guanidino group in
arginine, and agmatine is an arginine analogue with a
guanidino group. Being structurally similar to argi-
nine, agmatine has been known as a competitive
inhibitor of nitric oxide synthase (Auguet et al, 1995;
Galea et al, 1996). This suggests that agmatine may
protect the brain from ischemic injury by interfering
with nitric oxide signaling (Kim et al, 2004).
Stroke is one of the leading causes of death in most
of the developed countries with its incidence slowly
increasing worldwide (Bonita, 1992; Chalela et al,
2004). Edema is frequently observed in ischemic
stroke. Brain edema, defined as an abnormal increase
in brain water content, which leads to an expansion
of brain volume, has a crucial impact on morbidity
and mortality after stroke, in that it increases
intracranial pressure, favors herniations, and con-
tributes to additional ischemic injuries (Klatzo,
1985). Aquaporins (AQPs) are a family of water
channel proteins that facilitate the diffusion of water
through the plasma membrane (Agre et al, 2002).
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In the rodent brain, three AQPs have been clearly
identified, AQPs-1, -4, and -9 (Agre et al, 2004;
Badaut et al, 2002). AQP-1 has been detected in
epithelial cells of the choroid plexus (Nielsen et al,
1993), AQP-4 in astrocytes with a polarization on
astrocyte endfeet (Nielsen et al, 1997), and AQP-9 in
astrocytes of the white matter and in catecholami-
nergic neurons (Badaut et al, 2001, 2004). AQP-1 and
AQP-4 are permeable only to water and are presumed
to be involved in cerebrospinal fluid formation and
brain water homeostasis (Amiry-Moghaddam and
Ottersen, 2003). AQP-9 is an aquaglyceroporin, a
subgroup of the AQP family, and is permeable to
water and also glycerol, monocarboxylates, and urea
(Badaut and Regli, 2004). These three channels may
be implicated in water movements occurring during
the formation and resolution of cerebral edema after
ischemia.
On the basis of the above available reports, it was
hypothesized that agmatine may have neuroprotec-
tive effect on brain edema. The purpose of this study
was to investigate the protective effect of agmatine,
if any, for brain edema in ischemic brain damage and
also to investigate the expression of AQPs.
Materials and methods
Animals
ICR mice from Sam (Osan, Korea) were used for this study.
All animal procedures were performed according to a
protocol approved by the Yonsei University Animal Care
and Use Committee in accordance with NIH guidelines.
Stroke Model
Male ICR mice weighing 36±2 g were subjected to
transient middle cerebral artery occlusion (MCAO,
n=50). Animals were anesthetized with chloral hydrate
(400mg/kg) intraperitoneally. Depth of anesthesia was
assessed by toe pinch every 15mins. In a separate set of
animals (n=5, agamatine treated; n=5, control), a femoral
arterial line was placed and physiologic parameters
including mean arterial blood pressure, arterial blood
gases, and rectal temperature were monitored before,
during, and after ischemia. Ischemia was induced using
an occluding intraluminal suture as described earlier (Lee
et al, 2001). In brief, an uncoated 15mm segment of 6-0
nylon monofilament suture with the tip rounded by a flame
was inserted into the arteriotomy and advanced under
direct visualization into the internal carotid artery 11mm
from the bifurcation to occlude the ostium of the middle
cerebral artery. After 2h, the suture was withdrawn and
surgical incisions were closed. Twenty-two hours later, the
animals were decapitated and the brains were removed;
1.5mm thick blocks were cut in the coronal plane, stained
with triphenyl tetrazolium chloride (Sigma, St Louis, MO,
USA) to delineate regions of infarction, and embedded in
paraffin. After paraffin embedding, 10mm thick sections were
stained with H&E and immunostained (Lee et al, 2001).
Treatment
Agmatine was dissolved in normal saline (100mg/kg IP,
Sigma, St Louis, MO, USA) and administered after the
suture was removed (agmatine, n=21). Controls received
normal saline in equivalent volumes (EC, n=18).
Assessment of Brain Edema and Infarct Volume
Brain swelling and infarct volumes were determined by
triphenyl tetrazolium chloride staining, using a computer-
assisted image analysis system (Optimas ver 6.1, Optimas,
Bothell, WA, USA), and corrected for the presence of
edema using earlier published methods (Kim et al, 2004;
Lee et al, 2001). The volume of infarct was expressed as a
percentage of the total area of ipsilateral hemisphere.
Brain Water Content
Mice were killed 22h after reperfusion, at the time point
of maximal brain edema formation. Brains were removed.
Hemispheres were separated and weighed to assess the wet
weight (WW). Thereafter, the hemispheres were dried for
24h at 1101C and the dry weight (DW) was determined
(Groger et al, 2005). Hemispheric water content (%) was
calculated using the following formula: ((WWDW)/
WW) 100 (%).
Blood–Brain Barrier Disruption
The integrity of the blood–brain barrier (BBB) was
investigated using Evans blue extravasation (Chan et al,
1991; Uyama et al, 1988). Evans blue dissolved at 2% in
saline (100 mL) was injected in the tail vein and allowed to
circulate for 90mins. The chest wall was then opened
under chloral hydrate anesthesia (400mg/kg, intraperito-
neally). Blood sample was obtained from the heart.
Animals were perfused transcardially with saline until
blue color was washed out from the effluent. Brains were
removed immediately and were separated into cortex,
hippocampus, striatum, and oligemia (the border area of
cerebral infarct) with weights taken. They were homo-
genized in 500mL of 50% trichloroacetic acid (weight/
volume), and centrifuged (10,000 r.p.m., 20mins). The
supernatant obtained was measured at 445nm using ELISA
reader. Evans blue content of the plasma was similarly
determined and the ratio of tissue to plasma Evans blue
content was calculated as tissue Evans blue (mg/g wet
weight)/plasma Evans blue (mg/g).
Immunohistochemical Staining for AQPs
Brains were fixed with 4% paraformaldehyde, and em-
bedded in paraffin. Brain sections were microtomed into
10 mm. Sections were immunostained with antibodies
against AQP-1 (Abcam, Cambridgeshire, UK), AQP-4, or
AQP-9 (Chemicon, Temecula, CA, USA), followed by an
appropriate fluorescein-conjugated secondary antibody
for double-labeled fluorescent immunohistochemistry.
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Double-labeled immunostaining was evaluated using a
fluorescence microscope (LSM 510 META, Carl Zeiss, Jena,
Germany). Immunostained controls were also prepared
simultaneously without primary antibodies. All incubation
steps were performed in a humidified chamber.
Immunoblotting of AQPs
The expressions of AQPs-1, -4, and -9 proteins in ischemic
injured brain were estimated by immunoblotting. Immuno-
blotting was performed using anti-AQPs and anti-actin
(Santa Cruz, Santa Cruz, CA, USA) antibodies. Equal
amounts of protein (100 mg) per condition were separated
on an 8% polyacrylamide gel and electrotransferred onto
Immobilon-NC membrane (Millipore, Bedford, MA, USA).
Immunoreactive bands were visualized with the ECL
detection system using Kodak X-AR film (Kim et al, 2004).
Statistical Analysis
Statistical tests to determine the differences between
groups were performed with Student’s t-test using SAS
ver. 8.01 (SAS Institute Inc., Cary, NC, USA). P-value
< 0.05 was considered significant. Data were expressed as
mean±standard deviation (s.d.).
Results
Agmatine Reduced the Brain Edema and the Infarct
Volume After Cerebral Ischemia
To investigate the effect of agmatine in ischemic
damage, brain swelling volume was assessed in
serial coronal sections of the mouse brain. The data
were summarized in Figure 1. The average total brain
swelling volume (cortical plus subcortical areas) in
experimental control group was 117.11%±2.37%
after 2 h MCAO and 22h reperfusion. In agmatine
treatment group, the average total brain swelling
volume was 102.73%±0.16% after 2 h MCAO and
22h reperfusion. Agmatine significantly reduced
brain swelling volume (14.38%±2.21%, P<0.01;
Figure 1).
Agmatine Decreased the Water Content in Ischemic
Injured Brain
The water content in ischemic injured mouse brains
at 22 h reperfusion was shown in Figure 2. In normal
control group, water content averaged 79.63%±
1.10% in the ipsilateral hemispheres. Ischemia led
to a significant increase in water content in the
ipsilateral hemispheres (88.23%±0.59%; Figure 2).
However, in agmatine treatment group, water content
was significantly decreased in the ipsilateral hemi-
spheres (80.61%±1.33%, P<0.01; Figure 2).
Agmatine Limited BBB Disruption
It is needed to confirm whether the brain edema is
vasogenic accompanied by BBB disruption or
cytotoxic without BBB disruption. At 24h after
ischemic injury, Evans blue contents in the
striatal, hippocampal, and cerebral cortical area of
agmatine treatment group (2.74±0.307; 3.08±0.134;
1.14±0.042) were significantly less than that of
experimental control group (4.90±0.120 in striatum;
4.24±0.135 in hippocampus; 1.96±0.110 in cerebral
cortex, P<0.05; Table 1). However, in the oligemia
area (the border area of cerebral infarct), there is no
difference observed between experimental control
(2.44±0.157) and agmatine treatment group
(2.50±0.145; Table 1).
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Figure 1 Brain edema and infarct volume on cerebral ischemia. Agmatine reduced infarct volume and brain swelling after ischemic
injury. (A) Serial coronal sections (1.5mm of thickness) of mouse brain stained with 2% triphenyl tetrazolium chloride solution.
(B) Graph of brain swelling percent (%) 22h after 2 h MCAO (*P<0.05; **P<0.01 versus EC). Data were expressed as
mean±s.d. Gray bar, noninfarct area; black bar, infarct area; EC (n=7), experimental control group; NC (n=4), normal control
group; Agm (n=9), agmatine treatment group.
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Agmatine Lessened the Expression of AQPs 22h After
2h of MCAO
It was well known that AQP-1 was expressed only in
epithelial cells of choroid plexus under normal
condition, but AQP-1 was strongly expressed in
endothelial cells 22 h after MCAO without agmatine.
AQP-1-positive endothelial cells were shown in
cortex (Figure 3A) and striatum (Figure 3B) except
oligemia (data not shown). The expression of
AQP-1 was reduced in endothelial cells of cortex
(Figure 3A) and striatum (Figure 3B) in agmatine
treatment group. Agmatine treatment also decreased
the expression of AQP-1 in blood vessels of the
choroid plexus (Figure 3C). Immunoblotting results
showed significantly less expression of AQP-1 in
agmatine treatment group compared with experi-
mental control at 22h after 2 h MCAO (P<0.05;
Figure 4). The other type of AQP, AQP-4 also
showed less expression but the obtained value
was not significantly different between with and
without agmatine treatment. However, the expres-
sion of AQP-9 was clearly decreased in agmatine
treatment group than experimental control group
(Figure 4), the obtained value was significant statis-
tically (P<0.05).
Discussion
It was shown that agmatine reduced brain swelling
and brain edema in experimental stroke in this
study. This effect of agmatine on the brain edema
is associated with the decrease in AQP-1 expres-
sion and with the limitation of BBB disruption.
It also appears that agmatine lessens the expres-
sion of AQP-1 in endothelial cells in cerebral
ischemia.
Figure 2 Brain water content on cerebral ischemia. Brain water
content was analyzed as a measure of brain edema of the
ischemic hemisphere 22 h after 2 h MCAO. Agmatine decreased
the total water content of ischemic injured brain to normal level
(**P<0.01 versus IS of EC; +P<0.05 and + +P<0.01
versus LS of EC). Data are expressed as mean±s.d. EC (n=3),
experimental control group; NC (n=5), normal control group;
Agm (n=4), agmatine treatment group; IS, ipsilateral ischemic
side; LS, contralateral ischemic side.
Table 1 EB ratio (Evans blue (mg/g wet weight)/plasma Evans
blue (mg/g))
Oligemia Hippo Striatum Cortex
EC 2.44±0.157 4.24±0.135 4.90±0.120 1.96±0.110
Agm 2.50±0.145 3.08±0.134* 2.74±0.307* 1.14±0.042*
Agmatine treatment reduced the BBB disruption in hippo, striatum, and
cortex. (*P<0.05 versus EC.) Agm (n=3), agmatine treatment group;
EB, Evans blue; EC (n=3), experimental control group; Oligemia, the border
area of cerebral infarct.
Figure 3 Macrographs of AQP-1 immunofluorescence in the
ischemic injured brain 22h after 2 h MCAO with or without
agmatine. Blood vessel marked with factorVIII (red) was stained
with AQP-1 (green) in cortex (A) and striatum (B) of experimental
control (EC), but was not merged with AQP-1 (green) in cortex
(A) and striatum (B) of agmatine treatment group (Agm). AQP-1
(green) was boldly detected at blood vessel of the choroid plexus
of ipsilateral side (Ipsi) in experimental control (EC) but was not
in agmatine treatment group (Agm) (C). Scale bar is 50 mm.
Contra, contralateral side.
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There are two types of brain edema, cytotoxic
edema and vasogenic edema after brain injury, such
as brain trauma and stroke. Cytotoxic edema occurs
without the BBB disruption, but vasogenic edema
with the BBB disruption (The Korean Neurosurgical
Society, 2005). The disruption of BBB was observed
22h after 2 h MCAO in this study (Table 1). AQP-1
and AQP-4 are the two members of AQP family
known to be expressed in the central nervous system,
and it is possible that these proteins contribute to
water transport across the BBB (Dolman et al, 2005).
In a study of AQP-1 expression in human brain, a
small number of microvessels were positively
stained, but they were markedly upregulated in
endothelium in astrocytomas and metastatic carci-
nomas (Verkman, 2002). Function of BBB is known
to be impaired in such brain tumors, leading to
formation of edema (Saadoun et al, 2002). Down-
regulation of the tight-junction proteins claudin and
occludin has also been demonstrated in microvessels
in glioblastoma multiforme (Liebner et al, 2000).
Thus, loss of BBB function and the expression of
AQP-1 may both be regarded as downregulation of
BBB phenotype (Dolman et al, 2005). BBB disruption
was reduced with agmatine treatment compared with
experimental control. Earlier we had reported that
agmatine decreased the expression of matrix metal-
loproteinase-2 and the expression of matrix metallo-
proteinase-9 in cerebral ischemia (Kim et al, 2008)
and it was known that the early expression of matrix
metalloproteinases-2 or -9 is associated with BBB
disruption and the formation of vasogenic edema
after transient focal cerebral ischemia (Fujimura
et al, 1999; Gasche et al, 1999; Heo et al, 1999;
Rosenberg et al, 1998). These reports can explain the
possible mechanism of agmatine to limit BBB
disruption in this study.
Our present investigation showed that AQP-1 was
expressed in endothelial cells but not in endfoot of
astrocytes surrounding capillary vessel in ischemic
injured brain (Supplementary Figure 1). As of
now, this might be the first report that AQP-1 is
highly expressed in endothelial cells of choroid
plexus in the case of vasogenic edema after cerebral
ischemia to our knowledge. In normal rat brain,
AQP-1 transcript and protein expression are
restricted to the ventricular facing surface of choroid
plexus and AQP-1 is related to cerebrospinal fluid
secretion (Hasegawa et al, 1993; Masseguin et al,
2000). The expression of AQP-1 in the ventricular
facing surface of choroid plexus was reduced in
contralateral side but was not reduced in ipsilateral
side of ischemic injured hemisphere compared with
normal brain. This phenomenon may be because of
the controlled cerebrospinal fluid secretion through
dropping the expression of AQP-1 in the ventricular
facing surface of choroid plexus to decrease the
ascension of intracranial pressure caused by ipsilat-
eral swelling. In agmatine treatment group, its
expression in ipsilateral and contralateral side was
similar to normal group, but the expression of AQP-1
was little increased in endothelial cells of choroid
plexus in ipsilateral side compared with contralat-
eral side of ischemic injured hemisphere. On the
Figure 4 The expression of AQPs in the ischemic injured brain 22h after 2 h MCAO with or without agmatine by immunoblotting.
Optical densites (OD) of AQPs-1, -4, and -9 are expressed as the band density of each group. Data are expressed as mean±s.d.
Agmatine treatment significantly decreased the expression of AQPs-1 and -9 compared with experimental control (*P<0.05 versus
EC). NC (n=3), normal control group; EC (n=4), experimental control group; Agm (n=3), agmatine treatment group.
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basis of these results, agmatine treatment decreased
the expression of AQP-1 in endothelial cells of whole
injured brain tissue, such as cortex, striatum, and
choroid plexus.
The expression of AQP-4 mRNA is strongly induced
when BBB is preserved. However, the expression of
AQP-4 mRNA is reduced in astrocytes when BBB
is disrupted after brain trauma (Kim et al, 2006).
It explains that the expression of AQP-4 is much less
than that of AQP-1 in the brain tissue after MCAO
injury in this study (Figure 4 and Supplementary
Figure 2). The expression of AQP-4 was not signifi-
cantly changed but a reducing trend was obtained in
agmatine treatment group than in experimental control
group. Gunnarson et al (2008) reported that AQP-4
phosphorylation is related to nitric oxide in astrocyte.
It is possible that agmatine would suppress the expres-
sion of AQP-4 in astrocyte by inhibiting nitric oxide
synthesis (Auguet et al, 1995; Galea et al, 1996).
It was published that AQP-9 protein is upregulated
on reactive astrocytes in the border of the infarct after
transient MCAO in mice (Badaut et al, 2001) and
AQP-9 showed a significant induction at 24h, with
expression increasing gradually with time, without
correlation to swelling (Ribeiro et al, 2006). These
reports suggest that the decreased expression of
AQP-9 in agmatine treatment group is not directly
related to the reduced brain edema after cerebral
ischemia by agmatine treatment.
In conclusion, agmatine attenuates brain edema by
limiting BBB disruption and blocking the accumula-
tion of brain water content through lessening the
expression of AQP-1 in endothelial cells in cortex,
striatum, and choroid plexus after cerebral ischemia,
suggesting that agmatine may have therapeutic
potential in treatment of brain edema after brain
injury, such as stroke and brain trauma.
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